Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus

Archives of Dermatological Research

Volumn 302, Issue 2, 2010, Pages 131-137

  Lubaki, L J ^a,b   Ghanem, G ^b   Vereecken, P ^a,b   Fouty, E ^c   Benammar, L ^a   Vadoud Seyedi, J ^a   Dell'Anna, M L ^d   Briganti, S ^d   Picardo, M ^d   Heenen, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Pimecrolimus; Tacrolimus; Time kinetics; Vitiligo

Indexed keywords

ALPHA TOCOPHEROL; PIMECROLIMUS; TACROLIMUS; ANTIOXIDANT; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MELANOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SERUM; SKIN PIGMENTATION; TIME; TREATMENT OUTCOME; VITILIGO; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SKIN PIGMENTATION; TACROLIMUS; VITILIGO;

EID: 77449155803     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-009-0973-3     Document Type: Article

References (35)

1. D Agrawal EM Shajil YS Marfatia R Begum 2004 Study on the antioxidant status of vitiligo patients of different age groups in Baroda Pigment Cell Res 17 289 294 10.1111/j.1600-0749.2004.00149.x 15140075 (Pubitemid 38724560)
2. M Akyol VK Celik S Ozcelik M Polat M Marufihah A Atalay 2002 The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA Eur J Dermatol 12 24 26 1:CAS:528: DC%2BD38Xit1artL4%3D 11809591
3. S Alaiti S Kang VC Fiedler, et al. 1998 Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children J Am Acad Dermatol 38 69 76 10.1016/S0190-9622(98)70541-9 1:STN:280:DyaK1c7gslyqtQ%3D%3D 9448208 (Pubitemid 28100468)
4. A Alomar J Berth-Jones JD Bos, et al. 2004 The role of topical calcineurin inhibitors in atopic dermatitis Br J Dermatol 151 Suppl 70 3 27 10.1111/j.1365-2133.2004.06269.x 1:CAS:528:DC%2BD2MXnslWlug%3D%3D 15548171 (Pubitemid 40023628)
5. IF Benzie JJ Strani 1996 The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay Anal Biochem 239 70 76 10.1006/abio.1996.0292 1:CAS:528:DyaK28XksFCmt7Y%3D 8660627 (Pubitemid 26256285)
6. A Billich H Aschauer A Aszodi A Stuetz 2004 Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus Int J Pharm 269 29 35 10.1016/j.ijpharm.2003.07. 013 1:CAS:528:DC%2BD3sXpvFeksLs%3D 14698574 (Pubitemid 38032821)
7. JS Comaish JS Greener 1976 The inhibiting effect of soft paraffin on the Kobner response in psoriasis Br J Dermatol 94 195 200 10.1111/j.1365-2133.1976. tb04370.x 1:STN:280:DyaE287js1ahsw%3D%3D 1252350
8. ML Dell'Anna V Maresca S Briganti E Camera M Falchi M Picardo 2001 Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo J Invest Dermatol 117 908 913 10.1046/j.0022-202x.2001.01459. x 11676831 (Pubitemid 33001210)
9. ML Dell'Anna S Urbanelli A Mastrofrancesco, et al. 2003 Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients Pigment Cell Res 16 553 559 10.1034/j.1600-0749.2003.00087.x 12950736 (Pubitemid 37093036)
10. LA Drake SM Dinehart ER Farmer, et al. 1996 Guidelines of care for vitiligo J Am Acad Dermatol 35 620 626 10.1016/S0190-9622(96)90691-X 1:STN:280:DyaK2s%2Fht1Ckuw%3D%3D 8859294 (Pubitemid 26427070)
11. B Gabryel M Chalimoniuk A Stolecka K Waniek J Langfort A Malecki 2006 Inhibition of arachidonic acid release by cytosolic phospholipase A2 is involved in the antiapoptotic effect of FK506 and cyclosporin a on astrocytes exposed to simulated ischemia in vitro J Pharmacol Sci 102 77 87 10.1254/jphs.FP0060605 1:CAS:528:DC%2BD28XhtVOmtL3E 16990701 (Pubitemid 44440970)
12. PE Grimes T Soriano MT Dytoc 2002 Topical tacrolimus for repigmentation of vitiligo J Am Acad Dermatol 47 789 791 10.1067/mjd.2002.126250 12399778 (Pubitemid 35239348)
13. L Iamele R Fiocchi A Vernocchi 2002 Evaluation of an automated spectrophotometric assay for reactive oxygen metabolites in serum Clin Chem Lab Med 40 673 676 10.1515/CCLM.2002.115 1:CAS:528:DC%2BD38Xnsl2ltb8%3D 12241012
14. AJ Kanwar S Dogra D Parsad 2004 Topical tacrolimus for the treatment of childhood vitiligo in Asians Clin Exp Dermatol 29 589 592 10.1111/j.1365-2230. 2004.01632.x 1:STN:280:DC%2BD2crotVKrtQ%3D%3D 15550128 (Pubitemid 39573641)
15. S Kato H Nishio M Ogura K Takeuchi 2007 Tacrolimus (FK506), an immunosuppressive agent, prevents indomethacin induced small intestinal ulceration in the rat: inhibition of inducible nitric oxide synthase expression J Pharmacol Sci 103 1 40 47 10.1254/jphs.FP0061181 1:CAS:528: DC%2BD2sXhvFGnu74%3D 17202747 (Pubitemid 46175594)
16. R Koca F Armutcu HC Altinyazar A Gurel 2004 Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo Clin Exp Dermatol 29 406 409 10.1111/j.1365-2230.2004.01524.x 1:STN:280:DC%2BD2czkt1ylug%3D%3D 15245542 (Pubitemid 38980375)
17. C-CE Lan G-S Chen M-H Chiou C-S Wu C-H Chang H-S Yu 2005 FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo Br J Dermatol 153 498 505 10.1111/j.1365-2133.2005.06739.x 1:CAS:528:DC%2BD2MXhtVOrtr3I 16120133 (Pubitemid 41248203)
18. AY Lee NH Kim WI Choi YH Youm 2005 Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo J Invest Dermatol 124 976 983 10.1111/j.0022-202X.2005.23667.x 1:CAS:528:DC%2BD2MXktFKnt7Y%3D 15854039 (Pubitemid 40629099)
19. AM Marsland CEM Griffiths 2002 The macrolide immunosuppressants in dermatology: mechanisms of action Eur J Dermatol 12 618 622 1:CAS:528: DC%2BD38Xps1yrtr4%3D 12459545
20. FA Mayoral C Gonzalez NS Shah C Arciniegas 2003 Repigmentation of vitiligo with pimecrolimus cream: a case report Dermatology 207 322 323 10.1159/000073099 14571079 (Pubitemid 37329207)
21. P Nghiem G Pearson RG Langley 2002 Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin, treating atopic dermatitis J Am Acad Dermatol 46 228 241 10.1067/mjd.2002.120942 11807435 (Pubitemid 34118380)
22. MD Njoo PI Spuls JD Bos W Westerhof PM Bossuyt 1998 Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature Arch Dermatol 134 1532 1540 10.1001/archderm.134.12.1532 1:STN:280: DyaK1M%2Fpt1enuw%3D%3D 9875190 (Pubitemid 29009253)
23. Nordlund JJ, Ortonne J-P (1998) Vitiligo vulgaris. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P (eds) The pigmentary system. Physiology and pathophysiology, 1st edn. Oxford University Press, Oxford, pp 513-531
24. N Otberg H Richter H Schaefer U Blume-Peytavi W Sterry J Lademann 2004 Variations of hair follicle size and distribution in different body sites J Invest Dermatol 122 14 19 10.1046/j.0022-202X.2003.22110.x 1:CAS:528: DC%2BD2cXmsFCmtA%3D%3D 14962084 (Pubitemid 38114633)
25. A Paller LF Eichenfield DYM Leung M Appel 2001 A 12 week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients J Am Acad Dermatol 44 47 57 10.1067/mjd.2001.109813 (Pubitemid 32049029)
26. S Passi A Morrone M Picardo C De Luca F Ippolito 1991 Blood level of vitamin E, polyunsatured fatty acids of phospholipids, lipoperoxides and glutathione peroxidase activity in patients with seborrheic dermatitis J Dermatol Sci 2 171 178 10.1016/0923-1811(91)90064-5 1:STN:280: DyaK3Mzks1WhtQ%3D%3D 1831657
27. S Sakuma Y Higashi N Sato T Sasakawa T Sengoku Y Ohkubo T Amaya T Goto 2001 Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids) Int Immunopharmacol 1 6 1219 1226 10.1016/S1567-5769(01)00059-5 1:CAS:528:DC%2BD3MXktFyhurY%3D 11407316 (Pubitemid 32434437)
28. DN Sauder 2004 Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions J Cutan Med Surg 8 Suppl 3 3 12 10.1007/s10227-004-0803-3 15647861 (Pubitemid 40685108)
29. KU Schallreuter G Chiuchiarelli E Cemeli, et al. 2006 Estrogens can contribute to hydrogen peroxide generation and quinone-mediated DNA damage in peripheral blood lymphocytes from patients with vitiligo J Invest Dermatol 126 1036 1042 10.1038/sj.jid.5700257 1:CAS:528:DC%2BD28XjsFSqsb4%3D 16528352
30. DA Smith SJ Tofte JM Hanifin 2002 Repigmentation of vitiligo with topical tacrolimus Dermatology 205 301 303 10.1159/000065845 1:STN:280: DC%2BD38njvFygtQ%3D%3D 12399684 (Pubitemid 36158546)
31. K Tanaka N Fujita M Yoshioka N Ogawa 2001 Immunosuppressive and non-immunosuppressive immunophilin ligands improve H2O2-induced cell damage by increasing glutathione levels in NG108-15 cells Brain Res 889 225 228 10.1016/S0006-8993(00)02851-1 1:CAS:528:DC%2BD3MXpsFeksA%3D%3D 11166708 (Pubitemid 32146286)
32. EA Tanghetti 2003 Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series Cutis 71 158 162 12635898
33. LB Travis JM Weinberg NB Silverberg 2003 Successful treatment of vitiligo with 0.1% tacrolimus ointment Arch Dermatol 139 571 574 10.1001/archderm.139.5. 571 12756092 (Pubitemid 36576372)
34. EJ Van Leent HJ De Vries ME Ebelin P Burtin G Scott JD Bos 2007 Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year J Dermatol Treat 18 1 19 22 10.1080/09546630601121037 (Pubitemid 46410632)
35. DC Whiteman PG Parsons AC Green 1999 Determinants of melanocyte density in adult human skin Arch Dermatol Res 291 511 516 10.1007/s004030050446 1:STN:280:DC%2BD3c%2FgvVOisg%3D%3D 10541882 (Pubitemid 29484132)